US2010120864A1PendingUtilityA1
2-aminooxazolines as taar1 ligands

Assignee: GALLEY GUIDOPriority: Feb 2, 2007Filed: Dec 16, 2009Published: May 13, 2010
Est. expiryFeb 2, 2027(~0.6 yrs left)· nominal 20-yr term from priority
Inventors:Guido Galley Katrin Groebke Zbinden Roger Norcross Henri Stalder
A61P 9/00A61P 3/06A61P 3/04A61P 25/06A61P 25/08A61P 25/20A61P 25/24A61P 25/00A61P 3/00A61P 25/16A61P 25/18A61P 3/10A61P 25/22A61P 25/28A61P 25/30C07F 7/0812C07D 413/12C07D 263/28C07D 413/06C07D 413/04A61K 31/422A61K 31/421
PatentIndex Score
Cited by
References
Claims
Abstract

The invention relates to compounds of formula I wherein X, Y, R 1 , R 2 , and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
Claims

exact text as granted — not AI-modified
1 . A method of treating a disorder selected from the group consisting of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson&#39;s disease, neurodegenerative disorders, Alzheimer&#39;s disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders comprising administering to an individual a therapeutically effective amount of a compound of formula I 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is hydrogen, deuterium, tritium, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, halogen, phenyl optionally substituted by halogen, phenyloxy, benzyl, benzyloxy, —COO-lower alkyl, —O—(CH 2 ) o —O-lower alkyl, NH-cycloalkyl, cycloalkyl or tetrahydropyran-4-yloxy, wherein the substituents for n&gt;1 are the same or different; 
 X is a bond, —CHR—, —CHRCHR′—, —OCH 2 —, —CH 2 OCHR—, —CH 2 CH 2 CH 2 —, —SCH 2 —, —S(O) 2 CH 2 —, —CH 2 SCH 2 —, —CH 2 N(R)CH 2 —, -cycloalkyl-CH 2 — or SiRR′—CH 2 —; 
 R and R′ are each independently hydrogen, lower alkyl or lower alkyl substituted by halogen; 
 R 2  is hydrogen, phenyl or lower alkyl; 
 Y is phenyl, naphthyl, thiophenyl, pyridinyl, cycloalkyl, 1,2,3,4-tetrahydro-naphthalen-2-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl or benzo[1,3]dioxol-5-yl; 
 n is 0, 1, 2 or 3; and 
 o is 2 or 3; 
 
     or of a pharmaceutically suitable acid addition salt thereof. 
   
   
       2 . The method of  claim 1 , wherein X is a bond. 
   
   
       3 . The method of  claim 2 , wherein Y is phenyl, substituted by one or more halogen atoms. 
   
   
       4 . The method of  claim 3 , wherein the compound administered is selected from the group consisting of
 (S)-4-(2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,3-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3,4-dichlorophenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,(S)-4-(3,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,3-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine;   (S)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,4-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine;   (S)-4-(4-chloro-3-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-5-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(5-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(4-chloro-2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (−)-(R)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,5-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine,   (−)-(R)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine, and   (S)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       5 . The method of  claim 2 , wherein Y is phenyl substituted by CH 3 , CF 3 , OCH 3 , OCF 3  or OCH 2 -phenyl. 
   
   
       6 . The method of  claim 5 , which compound administered is selected from the group consisting of
 (RS)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-benzyloxy-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-p-tolyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine, and   (+)-(S)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       7 . The method of  claim 2 , wherein Y is phenyl substituted by phenyl, which is optionally substituted by halogen. 
   
   
       8 . The method of  claim 7 , which compound administered is selected from the group consisting of
 (RS)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine, and   (RS)-4-(4′-chloro-biphenyl-4-yl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       9 . The method of  claim 2 , wherein Y is phenyl substituted by OCH 3  or by halogen and CF 3 , halogen and CH 3 , halogen and cycloalkyl or by halogen and OCH 3 . 
   
   
       10 . The method of  claim 9 , wherein the compound administered is selected from the group consisting of
 (RS)-4-(3-chloro-4-methoxyphenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (−)-(R)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine, and   (S)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       11 . The method of  claim 1 , wherein X is CHR and Y is phenyl. 
   
   
       12 . The method of  claim 11 , wherein the compound administered is selected from the group consisting of
 (S)-4-(2-chloro-benzyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-trifluoromethyl-benzyl)-4,5-dihydro-oxazol-2-ylamine, and   (RS)-4-(2-fluoro-5-methyl-benzyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       13 . The method of  claim 1 , wherein X is CHRCHR′ and Y is phenyl. 
   
   
       14 . The method of  claim 13 , wherein the compound administered is selected from the group consisting of (R)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine,
 (S)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-3-methoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   ((S)-4-[2-(2,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,5-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-o-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-m-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-p-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (R)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-3-methyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-{2-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-ethyl}-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-3-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2,3-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(1-methyl-2-phenyl-ethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,5-difluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,5-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-dichloro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-dichloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-((S)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-((R)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-6-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2,4-dichloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-5-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine, and   (S)-4-[2-(5-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine.   
   
   
       15 . The method of  claim 1 , wherein X is OCH 2  and Y is phenyl. 
   
   
       16 . The method of  claim 15 , wherein the compound administered is selected from the group consisting of
 (S)-4-(4-fluoro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4-dichloro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,5-dichloro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-bromo-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,4-difluoro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine, and   (S)-4-(2-fluoro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       17 . The method of  claim 1 , wherein X is CH 2 OCHR and Y is phenyl. 
   
   
       18 . The method of  claim 17 , wherein the compound administered is (S)-4-benzyloxymethyl-4,5-dihydro-oxazol-2-ylamine. 
   
   
       19 . The method of  claim 1 , wherein X is —(CH 2 ) 3 — and Y is phenyl. 
   
   
       20 . The method of  claim 19 , wherein the compound administered is selected from the group consisting of
 (S)-4-(3-phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine and   (R)-4-(3-phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       21 . The method of  claim 1 , wherein X is —SCH 2 —, —S(O) 2 CH 2 —, or —CH 2 SCH 2 — and Y is phenyl. 
   
   
       22 . The method of  claim 21 , wherein the compound administered is selected from the group consisting of
 (R)-4-phenylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine,   (R)-4-benzenesulfonylmethyl-4,5-dihydro-oxazol-2-ylamine,   (R)-4-benzylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine, and   (R)-4-(4-chloro-phenylsulfanylmethyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       23 . The method of  claim 1 , wherein X is —CH 2 N(R)CH 2 —, cycloalkyl-CH 2 — or SiRR′—CH 2 — and Y is phenyl. 
   
   
       24 . The method of  claim 23 , wherein the compound administered is selected from the group consisting of
 (S)-4-[1-(4-chloro-phenyl)-cyclopropylmethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[1-(4-chloro-phenyl)-cyclobutylmethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(1-phenyl-cyclopropylmethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[(benzyl-ethyl-amino)-methyl]-4,5-dihydro-oxazol-2-ylamine, and   (R)-4-[(dimethyl-phenyl-silanyl)-methyl]-4,5-dihydro-oxazol-2-ylamine.   
   
   
       25 . The method of  claim 1 , wherein Y is naphthyl, pyridyl, cyclohexyl, 2,3-dihydrobenzo[1,4]dioxin or 1,2,3,4-tetrahydronaphthalen. 
   
   
       26 . The method of  claim 25 , wherein the compound administered is selected from the group consisting of
 (RS)-4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-naphthalen-1-yl-4,5-dihydro-oxazol-2-ylamine,   (R)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-naphthalen-2-ylmethyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(1,2,3,4-tetrahydro-naphthalen-2-yl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-methyl-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine, and   (S)-4-(2-cyclohexyl-ethyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       27 . A compound of formula I 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is hydrogen, deuterium, tritium, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, halogen, phenyl optionally substituted by halogen, phenyloxy, benzyl, benzyloxy, —COO-lower alkyl, —O—(CH 2 ) o —O-lower alkyl, NH-cycloalkyl, cycloalkyl or tetrahydropyran-4-yloxy, wherein the substituents for n&gt;1 are the same or different; 
 X is a bond, —CHR—, —CHRCHR′—, —OCH 2 —, —CH 2 OCHR—, —CH 2 CH 2 CH 2 —, —SCH 2 —, —S(O) 2 CH 2 —, —CH 2 SCH 2 —, —CH 2 N(R)CH 2 —, -cycloalkyl-CH 2 — or SiRR′—CH 2 —; 
 R and R′ are each independently hydrogen, lower alkyl or lower alkyl substituted by halogen; 
 R 2  is hydrogen, phenyl or lower alkyl; 
 Y is phenyl, naphthyl, thiophenyl, pyridinyl, cycloalkyl, 1,2,3,4-tetrahydro-naphthalen-2-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl or benzo[1,3]dioxol-5-yl; 
 n is 0, 1, 2 or 3; and 
 o is 2 or 3; 
 
     or of a pharmaceutically suitable acid addition salt thereof. 
   
   
       28 . The compound of  claim 1 , having formula I-A 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is halogen, for n&gt;1 the halogen atom is the same or different; 
 R 2  is hydrogen, phenyl or lower alkyl; and 
 n is 1, 2 or 3; 
 
     or a pharmaceutically suitable acid addition salt thereof. 
   
   
       29 . The compound of  claim 28 , which is selected from the group consisting of
 (S)-4-(2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,3-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3,4-dichlorophenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,3-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,4-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-3-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-5-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(5-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(4-chloro-2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (−)-(R)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,5-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine,   (−)-(R)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine, and   (S)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       30 . The compound of  claim 27 , having formula I-B 
     
       
         
         
             
             
         
       
       R 1  is CH 3 , CF 3 , OCH 3 , OCF 3  or OCH 2 -phenyl, wherein the substituents for n&gt;1 are the same or different; 
       R 2  is hydrogen, phenyl or lower alkyl; 
       n is 1, 2 or 3; 
     
     or a pharmaceutically suitable acid addition salt thereof. 
   
   
       31 . The compound of  claim 30 , which is selected from the group consisting of
 (RS)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-benzyloxy-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-p-tolyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine, and   (+)-(S)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       32 . The compound of  claim 27 , having formula I-C 
     
       
         
         
             
             
         
       
     
     wherein
 R 2  is hydrogen, phenyl or lower alkyl; 
 
     or a pharmaceutically suitable acid addition salt thereof. 
   
   
       33 . The compound of  claim 32 , which is selected from the group consisting of
 (RS)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine, and   (RS)-4-(4′-chloro-biphenyl-4-yl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       34 . The compound of  claim 27 , having formula I-D 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is halogen and CF 3 , halogen and CH 3 , halogen and cycloalkyl, or is halogen and OCH 3 ; and 
 R 2  is hydrogen, phenyl or lower alkyl; 
 
     or a pharmaceutically suitable acid addition salt thereof. 
   
   
       35 . The compound of  claim 34 , which is selected from the group consisting of
 (RS)-4-(3-chloro-4-methoxyphenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (−)-(R)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine, and   (RS)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine.   (S)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine   (RS)-4-(3-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine   (S)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine   (RS)-4-(3-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine or   (S)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       36 . The compound of  claim 27 , having formula I-E 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is halogen, CF 3  or CH 3 , wherein the substituents for n&gt;1 are the same or different; 
 R 2  is hydrogen, phenyl or lower alkyl; 
 R is hydrogen, lower alkyl or lower alkyl substituted by halogen; and 
 n is 1 or 2; 
 
     or a pharmaceutically suitable acid addition salt thereof. 
   
   
       37 . The compound of  claim 36 , which is selected from the group consisting of
 (S)-4-(2-chloro-benzyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-trifluoromethyl-benzyl)-4,5-dihydro-oxazol-2-ylamine, and   (RS)-4-(2-fluoro-5-methyl-benzyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       38 . The compound of  claim 27 , having formula I-F 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is hydrogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or is halogen, wherein the substituents for n&gt;1 are the same or different; 
 R and R′ are each independently hydrogen, lower alkyl or lower alkyl substituted by halogen; 
 R 2  is hydrogen, phenyl or lower alkyl; and 
 n is 0, 1, 2 or 3; 
 
     or a pharmaceutically suitable acid addition salt thereof. 
   
   
       39 . The compound of  claim 38 , which is selected from the group consisting of
 (R)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-3-methoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   ((S)-4-[2-(2,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,5-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-o-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-m-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-p-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (R)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-3-methyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-{2-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-ethyl}-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-3-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2,3-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(1-methyl-2-phenyl-ethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,5-difluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,5-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-dichloro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-dichloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-((S)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-((R)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-6-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2,4-dichloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-5-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine, and   (S)-4-[2-(5-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine.   
   
   
       40 . The compound of  claim 27 , having formula I-G 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is lower alkyl, lower alkyl substituted by halogen or halogen, wherein the substituents for n&gt;1 are the same or different; 
 R 2  is hydrogen, phenyl or lower alkyl; and 
 n is 0, 1, 2 or 3; 
 
     or a pharmaceutically suitable acid addition salt thereof. 
   
   
       41 . The compound of  claim 40 , which is selected from the group consisting of
 (S)-4-(4-fluoro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4-dichloro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,5-dichloro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-bromo-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,4-difluoro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine, and   (S)-4-(2-fluoro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       42 . The compound of  claim 27 , having formula I-H 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is hydrogen or halogen; and 
 n is 0 or 1; 
 
     or a pharmaceutically suitable acid addition salt thereof. 
   
   
       43 . The compound of  claim 42 , which is
 (S)-4-benzyloxymethyl-4,5-dihydro-oxazol-2-ylamine.   
   
   
       44 . The compound of  claim 27 , wherein X is —(CH 2 ) 3 — and Y is phenyl. 
   
   
       45 . The compound of  claim 44 , which is selected from the group consisting of
 (S)-4-(3-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine and   (R)-4-(3-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       46 . The compound of  claim 27 , wherein X is —SCH 2 —, —S(O) 2 CH 2 —, —CH 2 S(O) 2 CH 2 — or —CH 2 SCH 2 — and Y is phenyl. 
   
   
       47 . The compound of  claim 46 , which is selected from the group consisting of
 (R)-4-phenylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine,   (R)-4-benzenesulfonylmethyl-4,5-dihydro-oxazol-2-ylamine,   (R)-4-benzylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine, and   (R)-4-(4-chloro-phenylsulfanylmethyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       48 . The compound of  claim 27 , wherein X is —CH 2 N(R)CH 2 —, cycloalkyl-CH 2 — or SiRR′—CH 2 — and Y is phenyl. 
   
   
       49 . The compound of  claim 48 , which is selected from the group consisting of
 (S)-4-[1-(4-chloro-phenyl)-cyclopropylmethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[1-(4-chloro-phenyl)-cyclobutylmethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(1-phenyl-cyclopropylmethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[(benzyl-ethyl-amino)-methyl]-4,5-dihydro-oxazol-2-ylamine, and   (R)-4-[(dimethyl-phenyl-silanyl)-methyl]-4,5-dihydro-oxazol-2-ylamine.   
   
   
       50 . The compound of  claim 27 , wherein Y is naphthyl, pyridyl, cyclohexyl, 2,3-dihydrobenzo[1,4]dioxin or 1,2,3,4-tetrahydronaphthalen. 
   
   
       51 . The compound of  claim 50 , which is selected from theg group consisting of
 (RS)-4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-nap hthalen-1-yl-4,5-dihydro-oxazol-2-ylamine,   (R)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-naphthalen-2-ylmethyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(1,2,3,4-tetrahydro-naphthalen-2-yl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-methyl-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine, and   (S)-4-(2-cyclohexyl-ethyl)-4,5-dihydro-oxazol-2-ylamine.   
   
   
       52 . A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is hydrogen, deuterium, tritium, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, halogen, phenyl optionally substituted by halogen, phenyloxy, benzyl, benzyloxy, —COO-lower alkyl, —O—(CH 2 ) o —O-lower alkyl, NH-cycloalkyl, cycloalkyl or tetrahydropyran-4-yloxy, wherein the substituents for n&gt;1 are the same or different; 
 X is a bond, —CHR—, —CHRCHR′—, —OCH 2 —, —CH 2 OCHR—, —CH 2 CH 2 CH 2 —, —SCH 2 —, —S(O) 2 CH 2 —, —CH 2 SCH 2 —, —CH 2 N(R)CH 2 —, -cycloalkyl-CH 2 — or SiRR′—CH 2 —; 
 R and R′ are each independently hydrogen, lower alkyl or lower alkyl substituted by halogen; 
 R 2  is hydrogen, phenyl or lower alkyl; 
 Y is phenyl, naphthyl, thiophenyl, pyridinyl, cycloalkyl, 1,2,3,4-tetrahydro-naphthalen-2-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl or benzo[1,3]dioxol-5-yl; 
 n is 0, 1, 2 or 3; and 
 o is 2 or 3; 
 
     or of a pharmaceutically suitable acid addition salt thereof and a pharmaceutically acceptable carrier. 
   
   
       53 . The composition of  claim 52 , wherein the compound of formula I is selected from the group consisting of
 (S)-4-(2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,3-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3,4-dichlorophenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,3-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,4-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-3-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-5-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(5-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(4-chloro-2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (−)-(R)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,5-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine,   (−)-(R)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-benzyloxy-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-p-tolyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4′-chloro-biphenyl-4-yl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-chloro-4-methoxyphenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (−)-(R)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (+)-(S)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(3-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-chloro-benzyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-trifluoromethyl-benzyl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2-fluoro-5-methyl-benzyl)-4,5-dihydro-oxazol-2-ylamine,   (R)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-3-methoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   ((S)-4-[2-(2,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,5-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-o-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-m-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-p-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (R)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-3-methyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-{2-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-ethyl}-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-3-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2,3-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(1-methyl-2-phenyl-ethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,5-difluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,5-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-dichloro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3,4-dichloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-fluoro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(4-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-((S)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-((R)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-chloro-6-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2,4-dichloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-chloro-5-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(5-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-fluoro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-chloro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,4-dichloro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3,5-dichloro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(4-bromo-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-chloro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2,4-difluoro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(2-fluoro-phenoxymethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-benzyloxymethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(3-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine,   (R)-4-(3-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine,   (R)-4-phenylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine,   (R)-4-benzenesulfonylmethyl-4,5-dihydro-oxazol-2-ylamine,   (R)-4-benzylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine,   (R)-4-(4-chloro-phenylsulfanylmethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[1-(4-chloro-phenyl)-cyclopropylmethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[1-(4-chloro-phenyl)-cyclobutylmethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-(1-phenyl-cyclopropylmethyl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[(benzyl-ethyl-amino)-methyl]-4,5-dihydro-oxazol-2-ylamine,   (R)-4-[(dimethyl-phenyl-silanyl)-methyl]-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-naphthalen-1-yl-4,5-dihydro-oxazol-2-ylamine,   (R)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-naphthalen-2-ylmethyl-4,5-dihydro-oxazol-2-ylamine,   (RS)-4-(1,2,3,4-tetrahydro-naphthalen-2-yl)-4,5-dihydro-oxazol-2-ylamine,   (S)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(3-fluoro-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine,   (S)-4-[2-(2-methyl-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine, and   (S)-4-(2-cyclohexyl-ethyl)-4,5-dihydro-oxazol-2-ylamine   
     or a pharmaceutically suitable acid addition salt thereof.
Cited by (0)

No later patents cite this yet.
References (0)

No backward citations on record.